Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Graphite Bio, Inc. - Common Stock (NQ: GRPH )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Graphite Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers HOOKIPA Pharma (NASDAQ:HOOK) stock moved upwards by 27.0% to $2.54 during Friday's regular session. The current volume of 40.0 million shares is 1123.6% of... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022
Upgrades Roth Capital upgraded the previous rating for Denbury Inc (NYSE:DEN) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago... 
Via Benzinga
Graphite Bio Announces Participation in Upcoming Investor Conferences
From Graphite Bio, Inc.
Via Business Wire
3 Stocks Insiders Are Buying: Oracle, Consumer Portfolio Services And More
Although Dow Jones dipped more than 700 points this morning, there were a few notable insider buys. When insiders purchase shares, it ind... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Zogenix (NASDAQ:ZGNX) shares moved upwards by 67.2% to $26.15 during Wednesday's regular session. As of 12:30 EST, Zogenix's stock is trading at a volume... 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers ContraFect (NASDAQ:CFRX) stock mo... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers ContraFect (NASDAQ:CFRX) stock in... 
Via Benzinga
Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Disease
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease
From Graphite Bio, Inc.
Via Business Wire
61 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare... 
Via Benzinga
Exposures Product Safety
Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit
From Graphite Bio, Inc.
Via Business Wire
3 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go... 
Via Benzinga
Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National Convention
From Graphite Bio, Inc.
Via Business Wire
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Convention
From Graphite Bio, Inc.
Via Business Wire
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (... 
Via Benzinga
Exposures COVID-19
Graphite Bio Announces Participation in Upcoming September Investor Conferences
From Graphite Bio, Inc.
Via Business Wire
Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results
From Graphite Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Applied Molecular (NASDAQ:AMTI) shares increased by 19.38% to $35.54 during Friday's pre-market session. The market value of their outstanding shares is at $1.... 
Via Benzinga
Graphite Bio's Approach To Gene Editing Has BofA Securities and Morgan Stanley Bullish
A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc... 
Via Benzinga
The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2021
Upgrades For Bank of Marin Bancorp (NASDAQ: 
Via Benzinga
Opening Day: Wahlberg-backed Gym Owner F45 Opens Higher In Public Debut
Mark Wahlberg-backed F45 Training rose as much as 11% in its trading debut but fell near the offer price after its $325M IPO on Thursday. The listing was delayed by the COVID-19 pandemic and then... 
Via Talk Markets
Topics Initial Public Offering
Exposures COVID-19 Securities Market
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30) Ambrx Biopharma Inc. (NYSE... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.